IDH1 and glioma: The benefit from alkylating agent chemotherapy demonstrated in various RCTs (described later) has to be weighed against the potential long-term toxicities and the risk of inducing a hypermutator phenotype that is associated with a more malignant phenotype, in particular in patients with IDH-mutant gliomas, who have a longer life expectancy63,64.